Diabetic Kidney Disease

Nephrology
10
Pipeline Programs
5
Companies
7
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
5
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
360%
Peptide
240%
+ 3 programs with unclassified modality

On Market (2)

Approved therapies currently available

Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programs
1
1
LiraglutidePhase 4Peptide1 trial
INV-202Phase 21 trial
Active Trials
NCT05514548Completed265Est. Sep 2024
NCT02545738Completed32Est. May 2016
GS
Gilead SciencesFOSTER CITY, CA
4 programs
2
2
SELPhase 21 trial
SelonsertibPhase 2Small Molecule1 trial
SelonsertibPhase 1Small Molecule1 trial
SelonsertibPhase 1Small Molecule
Active Trials
NCT02509624Completed52Est. Dec 2015
NCT04026165Completed384Est. Sep 2021
NCT02177786Completed334Est. Aug 2016
ZyVersa Therapeutics
1 program
1
2HPβCDPhase 21 trial
Active Trials
NCT06489340Withdrawn0Est. Aug 2026
Providence Therapeutics
1 program
1
SemaglutidePhase 2Peptide1 trial
Active Trials
NCT05822609RecruitingEst. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskLiraglutide
ZyVersa Therapeutics2HPβCD
Providence TherapeuticsSemaglutide
Novo NordiskINV-202
Gilead SciencesSEL
Gilead SciencesSelonsertib
Gilead SciencesSelonsertib

Clinical Trials (7)

Total enrollment: 1,067 patients across 7 trials

NCT02545738Novo NordiskLiraglutide

Antiproteinuric Effects of Liraglutide Treatment

Start: Apr 2015Est. completion: May 201632 patients
Phase 4Completed
NCT06489340ZyVersa Therapeutics2HPβCD

P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

Start: Jun 2025Est. completion: Aug 20260
Phase 2Withdrawn
NCT05822609Providence TherapeuticsSemaglutide

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Start: Apr 2024Est. completion: Jun 2026
Phase 2Recruiting
NCT05514548Novo NordiskINV-202

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Start: Oct 2022Est. completion: Sep 2024265 patients
Phase 2Completed
NCT04026165Gilead SciencesSEL

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

Start: Jul 2019Est. completion: Sep 2021384 patients
Phase 2Completed
NCT02177786Gilead SciencesSelonsertib

Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease

Start: Jun 2014Est. completion: Aug 2016334 patients
Phase 2Completed
NCT02509624Gilead SciencesSelonsertib

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Start: Aug 2015Est. completion: Dec 201552 patients
Phase 1Completed

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,067 patients
Small Molecule is the dominant modality (60% of programs)
5 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)